TY  - JOUR
T1  - HOrmonal therapy for prostate cancer in men with heart disease
AU  - Agarwal N
Y1  - 2010/01/06
N1  - 10.1001/jama.2009.1931
JO  - JAMA
SP  - 32
EP  - 33
VL  - 303
IS  - 1
N2  - 
To the Editor: In the study by Dr Nanda and colleagues,1 although the adjusted hazard ratio for all-cause mortality with neoadjuvant androgen deprivation therapy (ADT) was less than 1.0 in men without comorbidities, the absolute death rate was higher in men who received neoadjuvant ADT (9.6%) than in men who did not (6.7%). Although the authors state that this can be explained by the more unfavorable prostate cancer prognostic factors for the neoadjuvant ADT group, the possibility that ADT promoted castration-refractory disease and all-cause mortality cannot be ruled out.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.1931
UR  - http://dx.doi.org/10.1001/jama.2009.1931
ER  -